State-by-State Breast Cancer Mortality Shows a Sharp 2024 Divide
In 2024, the age-adjusted rate of female breast cancer deaths in the United States was 18.7 per 100,000 females. Beneath that national average sits a clear geographic spread: the District of Columbia recorded the highest death rate at 24.1, while Rhode Island posted the lowest at 14.4.
Those numbers are not simply administrative markers. Breast cancer mortality reflects the combined effect of how early disease is found, how quickly treatment begins, whether patients can access high-quality surgery, systemic therapy, radiation, and follow-up, and how consistently those services are delivered across a state. A death-rate map, in practical terms, is a map of health-system performance layered over tumor biology.
What the 2024 Mortality Rate Means in Practice
The national rate of 18.7 deaths per 100,000 females is age-adjusted to the 2000 U.S. Census Bureau standard population, allowing comparisons across states with different age structures. That adjustment matters because breast cancer risk rises with age, and states with older populations would otherwise appear to fare worse simply because of demographic composition.
The spread from 14.4 to 24.1 indicates that women’s chances of dying from breast cancer are not distributed evenly across the country. Even within a single disease category, mortality can diverge when screening uptake, diagnostic speed, treatment continuity, and social barriers do not align. Late-stage presentation, interrupted therapy, and delayed access to specialty care all push mortality upward. When those forces accumulate, a state’s rate climbs long before that difference is obvious at the bedside.
DC’s rate of 24.1 stands well above the national figure, while Rhode Island’s 14.4 sits notably below it. Those two endpoints frame the entire distribution and make the variation hard to ignore.
Why Geographic Variation Persists
Breast cancer death rates are shaped by more than tumor subtype or individual risk. Screening patterns influence the stage at which disease is first detected. If mammography is delayed, inconsistently available, or less likely to be followed by timely diagnostic workup, cancers are more likely to be found after they have spread beyond the breast. Once the disease becomes advanced, survival drops and mortality rises.
Access to treatment is equally important. Modern breast cancer care depends on a chain of services: pathology review, receptor testing, surgery, radiation, endocrine therapy, chemotherapy, targeted therapy, and survivorship monitoring. Breaks in that chain can weaken outcomes even when the initial diagnosis is made on time. In states where patients face longer travel distances, fewer oncology specialists, insurance interruptions, or treatment delays, mortality can drift upward.
Social determinants also matter. Income, education, transportation, housing instability, and caregiving demands all affect whether a patient can complete treatment. The death rate often captures these pressures indirectly, because the system’s weakest links eventually surface in population mortality.
Why Age Adjustment Is Essential Here
The use of age-adjusted rates allows fairer comparisons among states. Breast cancer does not affect every age group equally, and raw counts alone would obscure the underlying pattern. A larger or older state could appear to carry a heavier burden simply because it has more women at ages where breast cancer is more common.
Age adjustment corrects for that distortion and leaves a cleaner signal: where mortality is truly higher, independent of age structure. In this case, the signal remains strong. The national average is one thing; the state-level separation is another, and the distance between the highest and lowest states is large enough to merit close public health attention.
Surveillance Data as a Clinical Warning System
This CDC snapshot comes from the National Center for Health Statistics and the National Vital Statistics System, using mortality data for 2024. Surveillance tables like this do not explain why a state’s mortality rate is high, but they define where to look first. They identify the places where prevention, screening, treatment access, and survivorship support deserve the most scrutiny.
For clinicians, the implications are straightforward. A patient’s outcome is still individual, but the environment in which care occurs is not. State-level mortality rates can point to diagnostic delays, uneven adherence to guideline-based care, or structural barriers that keep patients from receiving the full course of therapy. In breast cancer, those failures can translate into preventable deaths.
The Remaining Questions Behind the Map
This report provides a state-level mortality snapshot, not the underlying cause for each jurisdiction’s rate. It does not separate differences in incidence from differences in survival, and it does not identify how much of the variation is driven by stage at diagnosis, treatment completion, comorbidity burden, or population access to care. Those unanswered drivers are the next analytic layer needed to move from surveillance to intervention.
The numbers are still enough to show a national pattern with wide local gaps. Breast cancer mortality in 2024 was not uniform across the United States, and the difference between DC and Rhode Island shows how much geography can still shape the chance of dying from a disease that remains highly treatable when found early and managed consistently.